Department of Breast Surgery, The Affiliated Changzhou No. 2 People's Hospital of Nanjing Medical University, Changzhou, China.
Department of Breast Surgery, The Affiliated Changzhou No. 2 People's Hospital of Nanjing Medical University, Changzhou, China
Biosci Rep. 2018 Nov 15;38(6). doi: 10.1042/BSR20181090. Print 2018 Dec 21.
A major cause of failure in chemotherapy is drug resistance of cancer cells. Exosomes have been introduced to spread chemoresistance through delivering miRNAs. However, a systematic evaluation of the exosomal miRNA expression profiles responsible for chemoresistance is still lacking. In the present study, miRNA signature differentially expressed in exosomes derived from adriamycin-resistant (A/exo) and parental breast cancer cells (S/exo) were analyzed by microarray and the results were confirmed by PCR. A total of 309 miRNAs were increased and 66 miRNAs were decreased significantly in A/exo compared with S/exo. Specifically, 52 novel miRNAs with increased expression levels >16.0-fold in A/exo were identified. After prediction of target genes for 13 of 52 selected novel miRNAs, pathway analysis, gene ontology (GO) terms, and protein-protein interactions (PPIs) were constructed. The results implied that these selected exosomal miRNAs inhibited target genes involved in transcriptional misregulation in cancer, MAPK, and Wnt signaling pathways. Functional enrichment analysis demonstrated that the target genes were mainly responsible for protein phosphorylation, transcription regulation, molecular binding, and kinase activity. In summary, the current bioinformatics study of exosomal miRNAs may offer a new understanding into mechanisms of chemoresistance, which is helpful to find potential exosomal miRNAs to overcome drug insensitivity in future breast cancer treatment.
癌细胞的药物耐药性是化疗失败的一个主要原因。外泌体通过传递 miRNA 来传播耐药性。然而,对于负责耐药性的外泌体 miRNA 表达谱的系统评估仍然缺乏。在本研究中,通过微阵列分析了阿霉素耐药(A/exo)和亲本乳腺癌细胞(S/exo)来源的外泌体中差异表达的 miRNA 特征,并通过 PCR 进行了验证。与 S/exo 相比,A/exo 中共有 309 个 miRNA 显著上调,66 个 miRNA 显著下调。具体而言,在 A/exo 中发现了 52 个新型 miRNA,其表达水平上调了>16.0 倍。对 52 个选定的新型 miRNA 中的 13 个进行靶基因预测后,构建了通路分析、基因本体(GO)术语和蛋白质-蛋白质相互作用(PPIs)。结果表明,这些选定的外泌体 miRNA 抑制了癌中转录失调、MAPK 和 Wnt 信号通路中涉及的靶基因。功能富集分析表明,靶基因主要负责蛋白质磷酸化、转录调控、分子结合和激酶活性。综上所述,外泌体 miRNA 的当前生物信息学研究可能为耐药性机制提供新的认识,有助于在未来的乳腺癌治疗中寻找潜在的外泌体 miRNA 来克服药物不敏感性。